Clin cancer res:子宫内膜样卵巢癌或可采用子宫内膜癌的治疗策略

2020-08-01 QQY MedSci原创

与其他卵巢癌相比,子宫内膜样卵巢癌(ENOC)的预后通常更好。尽管如此,目前的患者治疗仍然遵循“一刀切”的方法。即使肿瘤分期提供了分层,个性化的治疗仍然是难以实现的。

与其他卵巢癌相比,子宫内膜样卵巢癌(ENOC)的预后通常更好。尽管如此,目前的患者治疗仍然遵循“一刀切”的方法。即使肿瘤分期提供了分层,个性化的治疗仍然是难以实现的。

鉴于ENOC与其子宫内膜相似物具有许多相同的临床和分子特征,Kremer等尝试在ENOC队列中研究TCGA激发的子宫内膜癌(EC)分子分型。

通过免疫组化和突变生物标志物将511例ENOC肿瘤分为四种EC激发的分子亚型:低风险POLE突变型(POLEmut)、中风险错配修复缺陷型(MMRd)、高风险p53异常型(p53abn)和无特殊分子的中风险 (NSMP)。对已建立的临床病理和亚型特异性特征进行生存分析。

POLEmut、MMRd、p53abn和NSMP的病例分别占3.5%、13.7%、9.6%和73.2%,预后各不相同(p<0.001),生存情况类似于EC。NSMP、MMRd、p53abn和POLEmut的中位OS分别是18.1年、12.3年、4.7年和未达到。在多变量分析中,亚型与分期、分级和残留疾病无关。

总结:EC启发的分子分类在ENOC中可提供独立的预后信息。本研究结果支持研究ENOC患者分子亚型的具体管理建议;如,当需要保留生育时,分子亚型可以提供指导。ENOC和EC之间的相似性表明ENOC患者可能受益于EC的管理策略。

原始出处:

Pauline Kremer,et al. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical cancer research. July 31,2020. DOI: 10.1158/1078-0432.CCR-20-1268

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708596, encodeId=9fbe1e0859668, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Jul 03 14:28:35 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805689, encodeId=aa90805689ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Sun Aug 02 06:19:24 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805618, encodeId=1c1380561854, content=这图真有意思,哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Aug 01 16:27:22 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805575, encodeId=1b5e8055e50f, content=讲解清楚全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f55408175, createdName=ms7000000646658052, createdTime=Sat Aug 01 11:04:16 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708596, encodeId=9fbe1e0859668, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Jul 03 14:28:35 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805689, encodeId=aa90805689ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Sun Aug 02 06:19:24 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805618, encodeId=1c1380561854, content=这图真有意思,哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Aug 01 16:27:22 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805575, encodeId=1b5e8055e50f, content=讲解清楚全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f55408175, createdName=ms7000000646658052, createdTime=Sat Aug 01 11:04:16 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-02 1240394fm61暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1708596, encodeId=9fbe1e0859668, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Jul 03 14:28:35 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805689, encodeId=aa90805689ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Sun Aug 02 06:19:24 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805618, encodeId=1c1380561854, content=这图真有意思,哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Aug 01 16:27:22 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805575, encodeId=1b5e8055e50f, content=讲解清楚全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f55408175, createdName=ms7000000646658052, createdTime=Sat Aug 01 11:04:16 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-01 ms3000000449926787

    这图真有意思,哈哈

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1708596, encodeId=9fbe1e0859668, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Jul 03 14:28:35 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805689, encodeId=aa90805689ad, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b972455532, createdName=1240394fm61暂无昵称, createdTime=Sun Aug 02 06:19:24 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805618, encodeId=1c1380561854, content=这图真有意思,哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Aug 01 16:27:22 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805575, encodeId=1b5e8055e50f, content=讲解清楚全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f55408175, createdName=ms7000000646658052, createdTime=Sat Aug 01 11:04:16 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-01 ms7000000646658052

    讲解清楚全面

    0

相关资讯

药品评审中心(CDE)已受理Pamiparib治疗卵巢癌的新药申请

生物技术公司百济神州今日宣布,中国药品监督管理局(NMPA)的药品评审中心(CDE)已接受百济神州PARP1和PARP2研究性抑制剂Pamiparib的新药申请(NDA)。

中国国家药品监督管理局将优先审查Pamiparib的新药申请

百济神州今日宣布,中国国家药品监督管理局(NMPA)药品评估中心(CDE)已授予Pamiparib新药审查优先权。

Cancer Immunol Immunother:卵巢癌免疫治疗方案的新研究探索

卵巢癌(OC)患者的标准治疗(SOC)一线治疗受到高复发率的困扰。多项研究表明,免疫系统在改变OC患者病程中的突出作用。目前正在探索的化疗免疫治疗方案包括奥瑞戈单抗,这是一种针对OC相关抗原碳水化合物

女性,腹痛半年,发热、呕吐1月,请诊断!

女性,腹痛半年,发热、呕吐1月,请诊断!

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌,III期研究失败

PD-L1单抗Tecentriq联合Avastin、紫杉醇和卡铂一线治疗晚期卵巢癌患者的III期临床,未达到无进展生存期的主要终点。

Eur J Cancer:HOXA9 meth-ctDNA可作为BRCA突变卵巢癌的生物标志物

聚(ADP-核糖)聚合酶(PARP)抑制剂已成为BRCA突变卵巢癌(OC)的一种新的治疗选择;然而,反应是可变的,并且缺乏预后和预测性生物标志物。因此,我们研究了循环肿瘤DNA(meth-ctDNA)